As COVID-19 vaccine candidates move into pivotal trials, developers and regulators are confronting new challenges, from getting a sufficient number of participants, to determining what will be needed to demonstrate safety and efficacy and how to deal with special populations.
The US FDA's Peter Marks, director of the Center for Biologics Evaluation and Research, and executives from companies developing COVID-19...







